Who We Are
GenesisTissue Inc. was founded in 2024 with the goal of revolutionizing regenerative tissues. GenesisTissue is a 3D bioprinting tissue company focused on designing and manufacturing personalized regenerative tissue implants for humans. We see a future where technology and biology come together to restore form and function. Using our proprietary 3D bioprinting and material science, we can finally move beyond implants made from legacy industrial materials, and towards living, regenerative solutions.
Our First Mission
A degradable, bioprinted breast tissue scaffold personalized for each patient, with the ability to become 100% native tissue in the breast.
367k
60%
1 in 5
~
women diagnosed with breast cancer
* 1
of women who undergo breast surgery have a portion of their breast removed through breast-conserving procedures, (i.e. lumpectomies)
* 2
patients need reoperations after initial lumpectomy surgery due to positive cancer margins
* 3
162k
* 4
breast reconstructive surgical procedures
305k
breast augmentations for cosmetic purposes
* 4
67k
breast implant removals. 41k from augmentation patients and 26k from reconstructive patients
* 4
* In the US, annually
1. American Cancer Society. Breast Cancer Facts & Figures 2024-2025.https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf
2. Nelson, Jonas A et al. “Analysis of a Trend Reversal in US Lumpectomy Rates From 2005 Through 2017 Using 3 Nationwide Data Sets.” JAMA surgery vol. 157,8 (2022): 702-711. doi:10.1001/jamasurg.2022.2065
3. McEvoy, Maureen P et al. “Update of the American Society of Breast Surgeons Toolbox to address the lumpectomy reoperation epidemic.” Gland surgery vol. 7,6 (2018): 536-553. doi:10.21037/gs.2018.11.03
4. American Society of Plastic Surgeons. 2024 ASPS Procedural Statistics Release. https://www.plasticsurgery.org/documents/news/statistics/2024/plastic-surgery-statistics-report-2024.pdf
